Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Nov 2;18(11):843-849.
doi: 10.1080/15384047.2017.1281491. Epub 2017 Jan 19.

Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib

Jia Gu  1 , Zhiqiong Wang  1 , Min Xiao  1 , Xia Mao  1 , Li Zhu  1 , Ying Wang  1 , Wei Huang  1
Affiliations
Case Reports

Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib

Jia Gu et al. Cancer Biol Ther. .

Abstract

Chronic myelomonocytic leukemia (CMML) is a heterogeneous neoplastic hematologic disorder with worse overall survival. Half of CMML have mutations, but case with concomitant mutations of DNA methyltransferase 3A (DNMT3A) and Internal tandem duplications of the juxtamembrane domain of FLT3 (FLT3-ITD) in CMML was not reported before. We reported a 51-year-old man who had CMML with concomitant mutations in DNMT3A and FLT3-ITD.The patient received decitabine and sorafenib combined treatment. In this report, we reviewed DNMT3A mutation and FLT3 mutation, and we reviewed treatment of decitabine and sorafenib. This report is significant. First: This is the first report on CMML with double-mutations of DNMT3A and FLT3-ITD. Second: It shows the importance of targeted drug in combined treatment of CMML.

Keywords: CMML; DNMT3A; FLT3-ITD; double-mutations; sorafenib.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Histopathology of bone marrow. (A) the Wright-Giemsa stain in bone marrow smear, the characteristic of monocytes (folded nuclei and delicate nuclear chromatin) is obvious. (B) a bone marrow biopsy specimen, the granulocytic component is most obvious in the biopsy specimen. (C,D) positive staining for CD15 and CD68 E, F: negativity for MPO and CD34.
Figure 2.
Figure 2.
Phenotypic abnormalities of monocytes detected by a multicolor flow cytometric approach at initial diagnosis.
Figure 3.
Figure 3.
Molecular genetics analysis of R882H DNMT3A mutation and FLT3-ITD mutation. (A) sequencing of R882H DNMT3A mutation. (B) PCR of FLT3-ITD mutation.
Figure 4.
Figure 4.
Change trend of the peripheral monocytosis.
See this image and copyright information in PMC

References

    1. Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol 2014; 12:172-178. PMID:24927265. - PubMed
    1. Sherdlow SH, Campo E, Harris NL. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC; Lyon: 2008, 4th edition:76.
    1. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, et al.. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J 2015; 5:e333; PMID:26230957; https://doi.org/10.1038/bcj.2015.53 - DOI - PMC - PubMed
    1. Zoi K, Cross NC. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. Int J Hematol 2015; 101:229-42; PMID:25212680; https://doi.org/10.1007/s12185-014-1670-3 - DOI - PubMed
    1. Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol 2014; 12:172-8. PMID:24927265 - PubMed

Publication types

MeSH terms

LinkOut - more resources